Navigation Links
Neurogen Proprietary Insomnia Compound Data for Two Studies,Presented at Associated Professional Sleep Societies Annual Meeting

cipates will occur in the future and include, but are not limited to, earnings estimates, statements that are not historical facts relating to Neurogen's future financial performance, its growth and business expansion, its financing plans, the timing and occurrence of anticipated clinical trials, and potential collaborations or extensions of existing collaborations. These statements are based on certain assumptions made by Neurogen based on its experience and perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate under the circumstances. Actual results may differ materially from those expressed or implied by such forward-looking statements as a result of various factors, including, but not limited to, risks associated with the inherent uncertainty of drug research and development, difficulties or delays in development, testing, regulatory approval, production and marketing of any of Neurogen's drug candidates, adverse side effects or inadequate therapeutic efficacy or pharmacokinetic properties of Neurogen's drug candidates or other properties of drug candidates which could make them unattractive for commercialization, advancement of competitive products, dependence on corporate partners, Neurogen's ability to retain key employees, sufficiency of cash to fund Neurogen's planned operations and patent, product liability and third party reimbursement risks associated with the pharmaceutical industry. Although Neurogen believes that its expectations are based on reasonable assumptions, it can give no assurance that the anticipated results will occur. For such statements, Neurogen claims the protection of applicable laws. Future results may also differ from previously reported results. For example, positive results or safety and tolerability in one clinical study provides no assurance that this will be true in future studies. Forward-looking statements represent the judgment of Neurogen's management
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Neurogen Announces Positive Results for Proprietary Insomnia Drug in Two Chronic Insomnia Clinical Trials
2. Neurogen Proprietary Insomnia Compound Data Presented at Associated Professional Sleep Societies Annual Meeting
3. Neurogen Proprietary Insomnia Compound Data Presented at American Psychiatric Association Annual Meeting
4. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
5. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
6. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
7. Cytogen Reports Publication Validating the Utility of its Proprietary ProChart Database
8. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
9. Helix BioMedix to Discuss Potential of Its Proprietary Peptides at the BIO International Convention
10. Integrated Biopharmas Proprietary Vaccine Technology Achieves Strong Positive Results
11. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
Post Your Comments:
(Date:12/24/2014)... N.Y. , Dec. 24, 2014 Kinex ... dosed with KX2-361 at Roswell Park Cancer Institute. ... small molecule drug that has shown potent inhibitory activity ... including those that are resistant to Temozolomide (T98G), the ... glioma. In a well-established brain tumor mouse model, KX2-361 ...
(Date:12/24/2014)... FARMINGTON, Conn. , Dec. 24, ... PTN), a biopharmaceutical company developing targeted, receptor-specific peptide ... unmet medical need and commercial potential, today announced ... of 2,050,000 shares of its common stock and ... its common stock.  Funds under the management of ...
(Date:12/24/2014)... 2014 ResMed (NYSE: RMD ) today ... Chinese medical device manufacturer BMC Medical Co., Ltd. ... masks listed below infringe ResMed,s patents, and entered an order ... the United States : , ... , Willow nasal pillows mask , iVolve full face ...
Breaking Medicine Technology:Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2
... SALT LAKE CITY, June 04, 2007 /PRNewswire-FirstCall/ -- ... a 340 patient,randomized Phase III clinical trial testing ... presented at the annual,American Society of Clinical Oncology ... results of this clinical study,which was conducted at ...
... III Data Presented at ASCO -, CHICAGO, ... that Soliris(TM) (eculizumab), a new treatment for,paroxysmal ... , is effective in patients diagnosed with ... (AA) or myelodysplastic,syndromes (MDS). Soliris significantly reduced ...
Cached Medicine Technology:Hyperthermia Plus Chemotherapy Nearly Doubles Disease-Free Survival,Compared to Chemotherapy Alone for Sarcoma Cancer Patients 2Hyperthermia Plus Chemotherapy Nearly Doubles Disease-Free Survival,Compared to Chemotherapy Alone for Sarcoma Cancer Patients 3Soliris Effective in PNH Patients With History of Aplastic Anemia,and Myelodysplastic Syndromes 2Soliris Effective in PNH Patients With History of Aplastic Anemia,and Myelodysplastic Syndromes 3Soliris Effective in PNH Patients With History of Aplastic Anemia,and Myelodysplastic Syndromes 4Soliris Effective in PNH Patients With History of Aplastic Anemia,and Myelodysplastic Syndromes 5Soliris Effective in PNH Patients With History of Aplastic Anemia,and Myelodysplastic Syndromes 6Soliris Effective in PNH Patients With History of Aplastic Anemia,and Myelodysplastic Syndromes 7
(Date:12/26/2014)... Yisrayl Hawkins, Pastor at The House of Yahweh in ... the Ferguson, Missouri unrest. Yisrayl starts his letter by showing ... it has only increased. , He continues in his ... there is a very specific reason for mankind and covers ... set of rules, or Laws that if followed would ensure ...
(Date:12/26/2014)... PA (PRWEB) December 26, 2014 Pentec ... Work in the state of Pennsylvania for 2014. The ... first statewide programs of its kind in the country. ... Foundation, the Pennsylvania Department of Community and Economic Development, ... Resource Management and the Central Penn Business Journal. ...
(Date:12/25/2014)... The click strand woven bamboo flooring ... Today, the business announces a click strand woven ... 30, 2015. , Click strand woven bamboo flooring ... a well-known brand in the bamboo industry. It ... reliable bamboo flooring supplier. , “We are happy ...
(Date:12/25/2014)... 26, 2014 Recently, iFitDress.com, the popular online ... has announced its new selection of black one-shoulder cocktail ... sale now; they are available at discounted prices, up to ... promotion will last for three weeks only. You know, we ... who are interested in our new items can visit our ...
(Date:12/25/2014)... December 25, 2014 Helen Harris’ RP ... Woodland Hills, California after an 8 year battle with ... Christmas Eve evening in her home in Woodland Hills ... breast cancer. , As the founder ... years, she pioneered and championed many of today's greatest ...
Breaking Medicine News(10 mins):Health News:Yisrayl Hawkins Pleads for Peace in Ferguson and Beyond in New Open Letter 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4
... ... to promote their first documentary film project entitled Now Serving. Now Serving will highlight the lives ... , ... Box Media LLC announces the launch of their blog site, My Apple Box , which ...
... ... that MedFusion®, of Dallas, Texas, has signed a business agreement to license laboratory ... ... 17, 2010 -- Sunquest Information Systems, Inc. ® , a leading provider ...
... ... can talk with an animated character - called an Avatar - who can help you make ... playing the role of an irate partner. , ... New York, NY (PRWEB) March 17, 2010 -- Imago,s new "marriage counseling" Avatar ...
... ... and potential physician leaders, through New York University,s Stern School of Business. , ... (Vocus) March 16, 2010 ... for its current and potential physician leaders. The 10-session program of New York University’s ...
... (Nasdaq: JAZZ ) announced today that Robert Myers , the company,s President, will present at the Barclays Capital 2010 Global Healthcare Conference on Wednesday, March 24, 2010 ... ... ... ...
... , March 16 TeamHealth Holdings, Inc. ("TeamHealth") ... of outsourced healthcare professional staffing and administrative services to hospitals ... today announced that its management will be presenting at the ... 2010 , at the Loews Miami Hotel, Florida . ...
Cached Medicine News:Health News:Announcing the Launch of My Apple Box 2Health News:Sunquest Information Systems Enters into Business Relationship with MedFusion of Dallas 2Health News:Avatar Meets Marriage Counseling; Take Imago Therapy for a Test Drive 2Health News:Avatar Meets Marriage Counseling; Take Imago Therapy for a Test Drive 3Health News:Summit Medical Group Prepares Physicians for Future Leadership 2Health News:Jazz Pharmaceuticals to Present at the Barclays Capital 2010 Global Healthcare Conference 2Health News:TeamHealth Holdings, Inc., to Present at Barclays Capital Global Healthcare Conference 2Health News:TeamHealth Holdings, Inc., to Present at Barclays Capital Global Healthcare Conference 3
One step Immunochromatographic Assay for the detection of Respiratory Syncytial Virus...
Rapid Immunoassay for the detection of Respiratory Syncytial Virus....
Rapid, visual assay for the presumptive qualitative detection of Respiratory Syncytial Virus (RSV) directly from nasopharyngeal specimens in neonatel and pediatric patients....
... The BD Directigen EZ RSV Test utilizes ... reagent and one device for rapid RSV detection. ... a method whereby dried reagents have already ... reduced to a two-step process, with clear-cut results ...
Medicine Products: